General information
ITM Isotope Technologies Munich SE
Lichtenbergstrasse 1
85748 Garching / Munich, Bavaria
Germany
Contact person: Ben Orzelek, Head of Investor Relations & Treasury
Company main phone: +49 (89) 32989866000
Company main fax: +49 (89) 32989866061
Website: https://itm-radiopharma.com
Year founded: | 2004
|
Source of foundation: | Independent foundation |
Corporate description / mission:
ITM Isotope Technologies Munich, a radiopharmaceutical biotech company, is focused on developing new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company’s radioisotopes with a range of targeting molecules.
State of ownership: Private / independent
Headquarters: HQ: Yes
Categorization
Sector: |
- Pharma (fully integrated)
|
Subsector: |
- Antibodies
- Peptides
- Other
|
Primary therapeutic areas: |
- Diseases of the ear / otology
- Neoplasms / cancer / oncology
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
|
Business model: |
- Manufacturer
- R&D
- Supplier / Distributor
|
Customer segments: |
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Number of Biotech Products
Description of products:
ITM-11
ITM-63
ITM-14D
ITM-22
ITM-24D, etc.
Collaborations & Clients
Partnering strategy / collaborations:
The company is always seeking innovative drug discovery partnerships, ideally fusing their target know-how with their leading radioisotope platform technologies to develop next generation diagnostic and therapeutic agents that will help fight serious and difficult to treat cancer diseases.